The natural history of non-Hodgkin lymphoma has remained the same over the past 30 years. However, treatment options have evolved during that time, and with that progress come confusion and controversy regarding the best therapeutic regimens to choose to provide patients the best possible care. This symposium will review treatment options for NHL, including chemotherapy, immunotherapy, radioimmunotherapy, and SCT. By familiarizing hematologists/oncologists with alternative therapeutic modalities and updating them on promising new therapies, prognosis for patients with NHL should improve as treatment decisions become clearer.

Accreditation Statement
Hemedicus, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit
Hemedicus designates this live activity for a maximum of 3 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.